Weight loss in early Parkinson’s linked to cognitive decline
Oct 20, 2022
Patients with Parkinson’s disease who have weight loss in the first year since diagnosis have a significantly faster decline in Montreal Cognitive Assessment scores.
Panel of 48 CSF proteins complements existing Alzheimer’s biomarkers
Sep 07, 2023
The CSF 48 panel plus existing biomarkers significantly improved the diagnostic performance for the outcomes studied.
Midlife cardiac structure and its change linked to cognition
Feb 02, 2022
A 25-year increase in left ventricular mass was linked to lower cognition on most tests; an increase in LAV was linked to lower global cognition.
Persistent pain in seniors linked to decline in physical function
Dec 07, 2022
However, those with persistent pain were no more likely to experience cognitive decline.
Most with Alzheimer’s disease, mild cognitive impairment would have been excluded from aducanumab...
Sep 16, 2021
Overall, 92.2, 91, and 85.5% of Medicare beneficiaries with Alzheimer’s disease-related disorders, Alzheimer’s disease, and mild cognitive impairment met at least one of the exclusion criteria.
Interventions for Alzheimer’s disease improve cognition in men, women
May 03, 2022
Individualized multidomain interventions are equally effective for improving cognition in women and men.
ASA: Nearly one in five people develop dementia after stroke
Feb 08, 2024
In the first year after stroke, there is an almost threefold higher risk for dementia.
Sleep architecture, sleep apnea affect global cognition
Jul 25, 2023
Better sleep consolidation and lack of obstructive sleep apnea were linked to better global cognition.
American Stroke Association, Feb. 9-11
Feb 22, 2022
The conference featured presentations that emphasized basic, clinical and translational medicine and provided insight into the prevention, management and treatment of stroke.
FDA approves second drug for Alzheimer’s disease, despite safety concerns
Jan 06, 2023
The approval of lecanemab-irmb (Leqembi) comes after controversial approval in 2021 of aducanumab (Aduhelm), which met with criticism over concerns about that drug’s effectiveness, safety and pricing.